Beyond adiposity: Molecular and clinical pathways linking obesity to cardiovascular disease
Saudi Journal of Obesity · 2023-01 · 11 (1) · 12-20
DOI: 10.4103/sjo.sjo_2_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Saudi Journal of Obesity, online erschienen am 16.11.2026. Verfasst von Aayed R. Alqahtani und 1 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Today, obesity is the second-most common preventable cause of cardiovascular disease (CVD) after smoking. Obesity increases the risk of developing CVD, heart failure, and atrial fibrillation (AF), among others. Beyond caloric surplus, three of the CVD mechanisms related to obesity are most significant. This review focuses on the connections seen in the clinic, the observable mechanisms in the literature on obesity spanning from 2021 to 2026, and CVDs. We investigate as to how stress and nitric oxide bioavailability, along with the obesity-related changes in the vascular and perivascular adipose tissue, affect vascular endothelium and atherogenesis. We describe the mechanisms of obesity-related hypertension (neurohormonal), passive venous hypertension caused by the compression of perirenal fat, sympathetic hyperactivity, and the leptin-induced renin–angiotensin–aldosterone system. This review also describes the obesity and heart failure with preserved ejection fraction (HFpEF)-related atrial remodeling (structural, electrical, and autonomic), epicardial adipose tissue, obesity-induced AF, and the HFpEF. We evaluate the combination of obstructive sleep apnea and insulin resistance, as well as the obesity paradox (the phenomenon of higher CVD patient survival associated with a higher body mass index). We evaluate the emerging therapy options for bariatric surgery and glucagon-like peptide-1 receptor agonists. With the SELECT and the STEP-HFpEF trials, these therapies are likely to change the management of obesity-related HFpEF and various CVDs. Considering obesity a systemic vasculo-cardiometabolic disease supports the view that precision cardiometabolic risk factor prevention should be prioritized over precision treatment of a single risk factor.
Zitieren
APA
Alqahtani, A. R., & Abdurabu, H. (2023). Beyond adiposity: Molecular and clinical pathways linking obesity to cardiovascular disease. Saudi Journal of Obesity, 11(1), 12-20. https://doi.org/10.4103/sjo.sjo_2_26
Vancouver
Alqahtani AR, Abdurabu H. Beyond adiposity: Molecular and clinical pathways linking obesity to cardiovascular disease. Saudi Journal of Obesity. 2023;11(1):12-20. doi:10.4103/sjo.sjo_2_26
BibTeX
@article{Alqahtani2023,
author = {Alqahtani, Aayed R. and Abdurabu, Hanan},
title = {Beyond adiposity: Molecular and clinical pathways linking obesity to cardiovascular disease},
journal = {Saudi Journal of Obesity},
year = {2023},
volume = {11},
number = {1},
pages = {12--20},
doi = {10.4103/sjo.sjo_2_26}
}
EUVIMED